1 / 15

Hemophilia A

Hemophilia A

yashb
Download Presentation

Hemophilia A

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemophilia-a

  2. 01 02 03 Introduction Epidemiology Pathogenesis 06 COMPANIES & DRUGS 04 05 07 09 08 Symptoms Treatment REPORT SCOPE Related report SWOT ANALYSIS About delveinsight 10

  3. Introduction Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.

  4. What is Hemophilia-a? Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.

  5. About Epidemiology

  6. Read Here • The total prevalent population of Hemophilia A in the 7MM in 2017 was 42,458 and expected to rise by 2030 • Severe Hemophilia A cases are more prominent in comparison to mild and moderate. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool. • According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017. • Around 30% of severe Hemophilia A cases develop inhibitors against the replacement factor VIII

  7. Hemophilia-a Pathogenesis 09 Hemophilia an is an x-connected draining issue brought about by insufficiency or complete shortfall of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Bleeding in hemophilia happens because of the disappointment of auxiliary hemostasis. Essential hemostasis and the development of platelet plug happens typically, yet adjustment of the attachment by fibrin is blemished in light of the age of deficient measures of thrombin.

  8. Hemophilia-a Symptoms 1. Unexplained and over the top seeping from cuts or wounds or after a medical procedure or dental work. 2. Numerous enormous or profound wounds. 3. Uncommon seeping after immunizations. 4. Agony, growing, or snugness in your joints.5. Blood in your pee or stool. 6. Nosebleeds without a known reason. 7. In newborn children, unexplained crabbiness.

  9. HEMOPHILIA-A TREATMENT Hemophilia A is a life-long condition. Currently, there is no cure, but researchers are actively engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of the defective blood factor gene, a person with hemophilia will be able to produce reasonable amounts of a factor on their own. Generally, Hemophilia A patients are provided with “On Demand” and “Prophylaxis” treatment. But Prophylaxis treatment option has gained importance in comparison to the on-demand treatment options. Currently, the major treatment options of Hemophilia A are Factor Replacement Concentrates, the source of which is either recombinant DNA technology or Human plasma-derive, and Bypassing agents. Moreover, this is an off-label treatment option, wherein Desmopressin Acetate (DDAVP) and Adjunctive therapies are also available for the management of Hemophilia A.

  10. Companies & Drugs in Hemophilia-a Market Drugs Companies • Esperoct (N8-GP; Turoctocogalfapegol) • Jivi (formerly BAY94-9027) • Wilate • Adynovate (Adynovi; BAX 855) • Afstyla (Lonoctocogalfa) • Kovaltry (BAY 81-8973) • Nuwiq (simoctocogalfa) • NovoEight (Turoctocogalfa) • Obizur • Kogenate FS (octocogalfa): • Xyntha (ReFacto AF) • Feiba • Hemlibra (Emicizumab-kxwh) • Sevenfact [coagulation factor VIIa (recombinant)-jncw] • Novo Nordisk • Bayer • Octapharma • Takeda • CSL Behring • Takeda • Pfizer • Roche (Chugai/ Genentech) • HEMA Biologics/LFB Pharmaceuticals

  11. SWOT Analysis W S O T

  12. Hemophilia-a Market Report Scope 1. The Hemophilia A report covers the descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies 2. Comprehensive insight has been provided into the Hemophilia A epidemiology and treatment in the 7MM 3. Additionally, an all-inclusive account of both the current and emerging therapies for Hemophilia A are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape 4. A detailed review of Hemophilia A market; historical and forecasted is included in the report, covering drug outreach in the 7MM 5. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hemophilia A market

  13. Related Report Market Reports Hemophilia B Market Insights, Epidemiology and Market Forecast,2030 Coagulation Factor Deficiency Market Insights, Epidemiology and Market Forecast,2030 Pipeline Reports Hemostasis—Pipeline Insight, 2021 Aplastic Anemia—Pipeline Insight, 2021 Thrombotic Thrombocytopenic Purpura— Pipeline Insight, 2021 Hemophilia A—Pipeline Insight, 2021

  14. About Delveinsight DelveInsight is a premier Business Consulting and Market Research firm that is involved in preparation of market research reports and analysis by in-house & external experts on pharmaceutical & biotech products, covering developed & emerging markets, for Pharma, biotech & marketing companies, in the healthcare & medical device industries. We are an one-stop destination for individuals, research institutions and companies seeking strategic advice and direction, as we provide global, regional and country-specific market research studies in the pharmaceutical and healthcare domain. DelveInsight has a purview of 3000+ market research reports, encompassing nearly every market category that will keep you up-to-date about the present and future market trends with competitive analysis of existing or emerging products & strategies. Our tactical guidance helps our clients stay ahead of the competition. Our research model is a unique mix of data analytics and market research methodology to help businesses achieve optimal performance.

  15. Thank You

More Related